Characteristic | Median OS | 95% CI | 3-year survival rate (%) | P-value | ||
---|---|---|---|---|---|---|
Age | <60 ≥ 60 | 32.0 27.0 | 20.9-43.1 12.6-41.4 | 44.2 31.0 | .053 | |
Sex | Male Female | 29.0 31.0 | 20.5-37.5 26.7-35.3 | 36.4 42.9 | .461 | |
Carcinoid symptom | Absent Present | 29.0 28.0 | 23.3-34.7 23.7-32.3 | 40.5 - | .646 | |
 | Pancreas | 43.0 | 23.4-62.6 | 45.3 |  | |
Origin | GI | 40.0 | 10.3-69.7 | 51.2 | .660 | |
 | Lung | 10.0 | - | - |  | |
Liver metastasis | Absent Present | 29.0 29.0 | 18.6-39.4 22.8-35.2 | 42.2 38.1 | .995 | |
 | 1 | 78.0 | 32.3-123.7 | 65.8 |  | |
Grade | 2-3 | 18.0 | 1.9-34.1 | 29.8 | .001 | |
 | Large | 15.0 | 2.8-27.2 | 13.9 |  | |
 | Small | 18.0 | 7.1-28.9 | 17.9 |  | |
 | 24-hour urine 5-HIAA (μmol/day) | <31.4 | 31.0 | 24.3-37.7 | 42.8 | .653 |
 |  | ≥ 31.4 | 46.0 | - | 66,7 |  |
Biomarkers | Â | Â | Â | Â | Â | Â |
 | Serum NSE (nmol/l) | <1.0 | 31.0 | - | 47.7 | .051 |
 |  | ≥ 1.0 | 7.0 | 4.3-9.7 | 26.8 |  |
 | Local treatment only | 43.0 | 23.1-62.9 | 53.0 |  | |
Treatment modality | Systemic treatment only | 23.0 | 0.4-45.6 | 38.0 | .245 | |
 | Both treatments | 29.0 | 23.6-34.4 | 43.0 |  |